IDEXX Laboratories, Inc.
IDXX Healthcare Medical - Diagnostics & Research NASDAQ
$608.41
$-10.51 (-1.70%)
Open: $607.59 | High: $615.48 | Low: $594.94 | Prev Close: $618.92
Market Cap: $48.58B
Volume: 560K | Avg: 515K
Last updated: March 09, 2026 at 02:02 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 566
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 46.51 |
| P/B Ratio | 30.35 |
| P/S Ratio | 11.29 |
| EPS | $13.08 |
| Beta | 1.70 |
| Shares Outstanding | 79.85M |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| SMA 50 | $667.69 |
| SMA 200 | $631.50 |
| Next Earnings | April 30, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 61.8% |
| Operating Margin | 31.6% |
| Net Margin | 24.6% |
| ROE | 69.8% |
| ROA | 31.6% |
| Debt/Equity | 0.67 |
| Current Ratio | 1.17 |
| Quick Ratio | 0.84 |
Balance Sheet
| Total Assets | $3.35B |
| Total Liabilities | $1.75B |
| Total Equity | $1.61B |
|
|
|
| Cash | $180.07M |
| Total Debt | $1.08B |
| Net Debt | $897.14M |
Income Statement
| Revenue | $4.30B |
| Gross Profit | $2.66B |
| Operating Income | $1.36B |
| Net Income | $1.06B |
|
|
|
| EBITDA | $1.47B |
| Revenue/Share | $53.73 |
Cash Flow
| Operating CF | $1.18B |
| CapEx | $124.68M |
| Free Cash Flow | $1.05B |
|
|
|
| Book Value/Share | $20.04 |
| Tangible Book/Share | $13.50 |
| Equity/Share | $20.04 |
Technical Indicators
| RSI (14) | 43.01 Neutral |
| MACD |
-10.87
Signal: -10.28
|
| Volatility | 28.51% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +16.63% |
| Sharpe Ratio | 0.59 Fair |
| Volatility (Ann.) | 43.61% High Risk |
| IDXX (1Y) | +16.63% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +3.59% |
Sector Comparison (Healthcare)
| Metric | IDXX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 46.51 | 27.29 | 91% |
| P/B Ratio | 30.35 | -20.11 | 94% |
| ROE (%) | 69.78% | -10.63% | 94% |
| Net Margin (%) | 24.62% | 9.02% | 81% |
| Stock Score | 566 | 543.0 | 60% |
| 1Y Return (%) | +16.63 % | +7.98 % | 65% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX | $608.41 | $628.86 | $639.89 | $637.72 | $668.24 | $631.63 | 43.01 | -10.87 | 28.51% | 130485 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the IDXX stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| IDXX | Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock | Positive | zacks.com | Read More |
| IDXX | IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It? | Neutral | zacks.com | Read More |
| IDXX | SONVY vs. IDXX: Which Stock Should Value Investors Buy Now? | Neutral | zacks.com | Read More |
| IDXX | IDEXX Laboratories (NASDAQ:IDXX) EVP Sells $1,115,574.06 in Stock | Neutral | defenseworld.net | Read More |
| IDXX | IDEXX Laboratories, Inc. $IDXX Shares Sold by Barclays PLC | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-03 | Underberg Sharon E. | officer: EVP, GC & Corporate Secretary | BUY | 197 | $505.53 | $99589 |
| 2026-03-03 | Underberg Sharon E. | officer: EVP, GC & Corporate Secretary | SELL | 197 | $505.53 | $99589 |
| 2026-03-03 | Hunt Nimrata | officer: Executive Vice President | SELL | 1758 | $634.57 | $1115577 |
| 2026-02-27 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | BUY | 197 | $505.53 | $99589 |
| 2026-02-27 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | SELL | 197 | $505.53 | $99589 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | BUY | 23326 | $141.60 | $3302962 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | SELL | 1281 | $650.67 | $833508 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | SELL | 1095 | $651.49 | $713378 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | SELL | 1669 | $652.49 | $1089013 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | director, officer: President and CEO | SELL | 1171 | $653.68 | $765455 |
Company Information
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| CEO | Jonathan J. Mazelsky |
| Employees | 11000 |
| Country | US |
| IPO Date | 1991-06-21 |
| Exchange | NASDAQ |
| Website | https://www.idexx.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category